Akero Therapeutics To Present At Morgan Stanley's 18th Annual Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif.,
A live webcast of the presentation and Q&A will be available through the investor relations section of the Company's website at www.akerotx.com. Following the live webcast, an archived replay will be available on the Company's website.
About
Akero is a cardio-metabolic NASH company dedicated to reversing the escalating NASH epidemic by developing pioneering medicines designed to restore metabolic balance and improve overall health of NASH patients. The Company's lead product candidate, AKR-001, is currently being evaluated in an ongoing Phase 2a clinical trial.
View original content to download multimedia:http://www.prnewswire.com/news-releases/akero-therapeutics-to-present-at-morgan-stanleys-18th-annual-global-healthcare-conference-301126806.html
SOURCE
Investor Contact: Christina Tartaglia, Stern Investor Relations, Inc., 212.362.1200, christina@sternir.com, or Media Contact: Carolyn Hawley, Canale Communications, 619.849.5382, carolyn@canalecomm.com